Whitson Bryan A, Leslie Daniel B, Kellogg Todd A, Maddaus Michael A, Buchwald Henry, Billington Charles J, Ikramuddin Sayeed
University of Minnesota Department of Surgery, Division of Gastrointestinal Surgery, Minneapolis, Minnesota 55455, USA.
J Surg Res. 2007 Oct;142(2):295-300. doi: 10.1016/j.jss.2007.03.036. Epub 2007 Jul 19.
The adipocyte influences eating behavior and metabolism via cytokine secretion. We report our findings of adipokine secretion in a cohort of diabetic and nondiabetic morbidly obese patients before and after Roux-en-Y gastric bypass (RYGB).
Ten morbidly obese subjects who underwent uncomplicated RYGB were studied: five were diabetic and nine were female. Nonfasting plasma levels of adiponectin, resistin, leptin, and tumor necrosis factor-alpha were determined preoperatively and 6 mo postoperatively. C-reactive protein (CRP) was followed as a marker of the metabolic syndrome.
The patient age was 42 +/- 11 y, and the preoperative BMI was 50 +/- 6 kg/m(2). The 6 mo BMI fell to 33 +/- 5 kg/m(2) (P < 0.0001), and there were no differences between diabetics and nondiabetics with respect to amount of weight loss. In nondiabetic patients, there were significant increases compared with preoperative levels for adiponectin, resistin, and tumor necrosis factor-alpha; leptin was significantly decreased while CRP was unchanged. CRP and leptin levels were both significantly lower (P < 0.05), while all other protein levels were unchanged in diabetic patients.
At 6 mo postoperation, RYGB significantly altered most adipokine levels for nondiabetic patients. Only CRP and leptin were changed in diabetic patients. All patients lost a significant amount of weight over 6 mo, suggesting a different metabolic effect between nondiabetic and diabetic patients after RYGB.
脂肪细胞通过分泌细胞因子影响饮食行为和新陈代谢。我们报告了在一组糖尿病和非糖尿病病态肥胖患者接受Roux-en-Y胃旁路术(RYGB)前后脂肪因子分泌的研究结果。
对10例接受无并发症RYGB的病态肥胖受试者进行研究:其中5例为糖尿病患者,9例为女性。术前及术后6个月测定非空腹血浆脂联素、抵抗素、瘦素和肿瘤坏死因子-α水平。随访C反应蛋白(CRP)作为代谢综合征的标志物。
患者年龄为42±11岁,术前BMI为50±6kg/m²。6个月时BMI降至33±5kg/m²(P<0.0001),糖尿病患者和非糖尿病患者在体重减轻量方面无差异。在非糖尿病患者中,脂联素、抵抗素和肿瘤坏死因子-α水平较术前显著升高;瘦素显著降低而CRP无变化。糖尿病患者的CRP和瘦素水平均显著降低(P<0.05),而所有其他蛋白水平无变化。
术后6个月,RYGB显著改变了非糖尿病患者的大多数脂肪因子水平。糖尿病患者仅CRP和瘦素发生变化。所有患者在6个月内体重均显著减轻,提示RYGB术后非糖尿病患者和糖尿病患者的代谢效应不同。